PR-POSITIVE BREAST CANCER
Clinical trials for PR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new PR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for PR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug trial halted midway: what happened?
Disease control TerminatedThis study tested an experimental drug called VLS-101 in 102 people with advanced solid tumors, including breast, lung, ovarian, stomach, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the t…
Matched conditions: PR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC
-
Promising combo study for advanced breast cancer halted early
Disease control TerminatedThis early-phase study tested a new drug (infigratinib) combined with tamoxifen for people with a specific type of advanced breast cancer (hormone receptor-positive, HER2-negative, with FGFR changes). The main goal was to find a safe dose by checking for side effects. Only 4 peop…
Matched conditions: PR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Jennifer Lee Caswell-Jin • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC